Advances in Retinopathy of Prematurity.

Author: Xiao Xuan XU ¹ ; Ya Jun WU ¹ ; Hong Yun WU ² ; Yu Xiang HU ¹ ; Yi CHENG ¹ ; Li YAN ¹ ; Jie RAO ¹ ; Na WU ¹ ; Xiao Rong WU ¹
Author Information

1. Department of Ophthalmology,the First Affiliated Hospital of Nanchang University,Nanchang 330006,China.
2. Department of Ophthalmology,Ganzhou People's Hospital,Ganzhou,Jiangxi 341000,China.
Publication Type:Journal Article
MeSH: Child; Humans; Infant, Newborn; Infant, Premature; Neovascularization, Pathologic; therapy; Retinopathy of Prematurity; drug therapy; surgery; Vascular Endothelial Growth Factor A; antagonists & inhibitors
From: Acta Academiae Medicinae Sinicae 2019;41(2):261-266
CountryChina
Language:Chinese
Abstract: Retinopathy of prematurity(ROP)is a pathological neovascularization with fibrotic changes in the fundus of premature infants.It is a major cause of preventable blindness in children in both developing and developed countries.Treatment of ROP has long been a hot research topic in ophthalmology and pediatrics.With a clearer knowledge of the pathogenesis of ROP,more basic and clinical studies have been carried out.The anti-vascular endothelial growth factor therapy and surgical treatment have become mature strategies,and a variety of therapeutic drugs including insulin-like growth factor-1,transforming growth factor-β,polyunsaturated fatty acids,and β-adrenergic receptor blockers have been developed.This article reviews the recent advances in ROP.